Naveen Pemmaraju: Our brand new MPN state-of-the-art review paper

Naveen Pemmaraju shared on LinkedIn:         .

“Super excited to share our brand new MPN (Myeloproliferative Neoplasms) state-of-the-art review paper.

‘Polycythemia Vera: Past, Present, and Future’ just out in Leukemia and Lymphoma led by Dr. Ami Patel and Dr. Naveen Pemmaraju, Lucia Masarova, Ruben Mesa, Gabriela Hobbs.”

Proceed to the article.
Source: Naveen Pemmaraju/LinkedIn

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director. His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.

He has been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020, which is one of the world’s most active BPDCN research programs. Dr. Pemmaraju is the recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. He is a well-known social media influencer and advocate.